Terms: = Breast cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2
26 results:
1. Lung Fibroblasts Take up breast cancer Cell-derived Extracellular Vesicles Partially Through mek2-dependent Macropinocytosis.
Wan Y; Zhao Y; Cao M; Wang J; Tran SV; Song Z; Hsueh BW; Wang SE
Cancer Res Commun; 2024 Jan; 4(1):170-181. PubMed ID: 38259097
[TBL] [Abstract] [Full Text] [Related]
2. Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.
Zheng ZZ; Xia L; Hu GS; Liu JY; Hu YH; Chen YJ; Peng JY; Zhang WJ; Liu W
Nucleic Acids Res; 2022 Oct; 50(18):10230-10248. PubMed ID: 36124682
[TBL] [Abstract] [Full Text] [Related]
3. O-GlcNAcylation of mek2 promotes the proliferation and migration of breast cancer cells.
Xu Y; Sheng X; Zhao T; Zhang L; Ruan Y; Lu H
Glycobiology; 2021 Jun; 31(5):571-581. PubMed ID: 33226073
[TBL] [Abstract] [Full Text] [Related]
4. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
[TBL] [Abstract] [Full Text] [Related]
5. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/mek2 inhibitor trametinib in patients with solid tumors.
Tolcher AW; Kurzrock R; Valero V; Gonzalez R; Heist RS; Tan AR; Means-Powell J; Werner TL; Becerra C; Wang C; Leonowens C; Kalyana-Sundaram S; Kleha JF; Gauvin J; D'Amelio AM; Ellis C; Ibrahim N; Yan L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):673-683. PubMed ID: 32062691
[TBL] [Abstract] [Full Text] [Related]
6. Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in breast Carcinoma using Nanofluidic Proteomics.
Urasaki Y; Fiscus RR; Le TT
Sci Rep; 2018 Jul; 8(1):9991. PubMed ID: 29968772
[TBL] [Abstract] [Full Text] [Related]
7. Direct binding of MEK1 and mek2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis.
Procaccia S; Ordan M; Cohen I; Bendetz-Nezer S; Seger R
Sci Rep; 2017 Feb; 7():43078. PubMed ID: 28225038
[TBL] [Abstract] [Full Text] [Related]
8. Identification of key genes in colorectal cancer using random walk with restart.
Cui X; Shen K; Xie Z; Liu T; Zhang H
Mol Med Rep; 2017 Feb; 15(2):867-872. PubMed ID: 28000901
[TBL] [Abstract] [Full Text] [Related]
9. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract] [Full Text] [Related]
10. mek2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression.
Huth HW; Albarnaz JD; Torres AA; Bonjardim CA; Ropert C
Cell Signal; 2016 Sep; 28(9):1283-1291. PubMed ID: 27181679
[TBL] [Abstract] [Full Text] [Related]
11. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway.
Luey BC; May FE
Mol Cancer; 2016 Jan; 15():8. PubMed ID: 26801096
[TBL] [Abstract] [Full Text] [Related]
12. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract] [Full Text] [Related]
13. Modulation of liver-intestine cadherin (Cadherin 17) expression, ERK phosphorylation and WNT signaling in EPHB6 receptor-expressing MDA-MB-231 cells.
Bhushan L; Tavitian N; Dey D; Tumur Z; Parsa C; Kandpal RP
Cancer Genomics Proteomics; 2014; 11(5):239-49. PubMed ID: 25331796
[TBL] [Abstract] [Full Text] [Related]
14. Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells.
Yi T; Zhai B; Yu Y; Kiyotsugu Y; Raschle T; Etzkorn M; Seo HC; Nagiec M; Luna RE; Reinherz EL; Blenis J; Gygi SP; Wagner G
Proc Natl Acad Sci U S A; 2014 May; 111(21):E2182-90. PubMed ID: 24782546
[TBL] [Abstract] [Full Text] [Related]
15. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Duncan JS; Whittle MC; Nakamura K; Abell AN; Midland AA; Zawistowski JS; Johnson NL; Granger DA; Jordan NV; Darr DB; Usary J; Kuan PF; Smalley DM; Major B; He X; Hoadley KA; Zhou B; Sharpless NE; Perou CM; Kim WY; Gomez SM; Chen X; Jin J; Frye SV; Earp HS; Graves LM; Johnson GL
Cell; 2012 Apr; 149(2):307-21. PubMed ID: 22500798
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J; Greshock J; Holbrook JD; Gilmartin A; Zhang X; McNeil E; Conway T; Moy C; Laquerre S; Bachman K; Wooster R; Degenhardt Y
Mol Cancer Ther; 2012 Mar; 11(3):720-9. PubMed ID: 22169769
[TBL] [Abstract] [Full Text] [Related]
17. Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets.
Yang L; Zhang L; Wu Q; Boyd DD
J Biol Chem; 2008 Dec; 283(50):35295-304. PubMed ID: 18940803
[TBL] [Abstract] [Full Text] [Related]
18. Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD).
Bentivegna S; Zheng J; Namsaraev E; Carlton VE; Pavlicek A; Moorhead M; Siddiqui F; Wang Z; Lee L; Ireland JS; Suyenaga K; Willis TD; Faham M; Seymour AB
Hum Mutat; 2008 Mar; 29(3):441-50. PubMed ID: 18186519
[TBL] [Abstract] [Full Text] [Related]
19. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract] [Full Text] [Related]
20. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract] [Full Text] [Related]
[Next]
